Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
APL 400-003 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| APL 400-003 | BIOLOGICAL | - |
Inclusion Criteria You may be eligible for this study if you: * Are 18 - 60 years old. * Are HIV-negative and in good health. * Are able to understand how infections such as HIV are spread. * Agree to use effective methods of birth control during the study. Exclusion Criteria You will not be eli...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
APL 400-003 is an investigational monoclonal antibody being studied for HIV infections. It is in Phase 1 clinical development and has been evaluated in completed trials involving HIV-seronegative volunteers. The drug is not approved and remains under investigation for its potential use in HIV.
APL 400-003 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company is conducting clinical research on this investigational monoclonal antibody for HIV infections.
APL 400-003 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, and the drug remains under study for HIV infections.
APL 400-003 has been studied in two completed Phase 1 trials: NCT00002231 and NCT00002232. Both trials evaluated the safety and effects of the drug, also known as GENEVAX-HIV, in HIV-seronegative volunteers in the United States.
Yes, APL 400-003 is also known as GENEVAX-HIV. Clinical trials NCT00002231 and NCT00002232 refer to the drug by this alternative name, and both names describe the same investigational monoclonal antibody for HIV infections.